OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today
that they have entered into a worldwide agreement for the development
and commercialization of OPKO’s long-acting hGH-CTP for the treatment of
growth hormone deficiency (GHD) in adults and children, as well as for
the treatment of growth failure in children born small for gestational
age (SGA) who fail to show catch-up growth by 2 years of age.
for OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting Human Growth Hormone (hGH-CTP) investment picks